Bristol-Myers Squibb presented long-term data from the Phase III CheckMate-067 trial this week showing that Opdivo (nivolumab) plus Yervoy (ipilimumab) modestly improved overall survival versus Opdivo alone as front-line therapy for advanced melanoma, but at the expense of significantly more serious adverse events and a lot more money. (See ViewPoints: Opdivo/Yervoy combo improves survival in melanoma, but toxicity remains an issue.)
To provide FirstWord readers with a better understanding of how the results may impact prescribing patterns in the advanced melanoma setting, we are hosting an expert call with a key opinion leader on early next week.
Key topics that will be discussed during the call include, among other things… how will the data impact use of the Opdivo and Yervoy combination and Opdivo as single-agent as a first-line therapy; how do Opdivo and Merck & Co.’s Keytruda (pembrolizumab) measure up in this setting; how might CheckMate-067 data impact future use of Keytruda in melanoma; takeaway message(s) from performance of Opdivo alone and with Yervoy in patients with PD-L1 high and low expression; and how significantly will CheckMate-067 data change the use of biomarker testing in melanoma patients?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to competition between and among immuno-oncology options in the advanced melanoma setting.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.